目的 观察吉西他滨联合多西他赛治疗复发或难治性骨肉瘤的有效性和安全性.方法 经病理确诊的28例复发或难治性骨肉瘤患者接受吉西他滨联合多西他赛治疗,具体方案为:吉西他滨1000mg/m2,静脉滴注,d1、d8；多西他赛75mg/m2,静脉滴注,d8,3周为1周期.化疗2个周期后,按照RECIST标准评价客观疗效.每周期按照NCI CTC 3.0分级标准评价药物毒性反应.结果 28例患者均可评价疗效,获PR 1例,SD 8例,PD 19例,有效率(RR)为3.6％ (1/28),疾病控制率(DCR)为32.1％ (9/28)；中位无疾病进展时间为6.0周(6～24周),中位总生存时间为11.0个月(3～26个月).主要毒副反应为骨髓抑制、胃肠道反应和乏力,未出现严重不良反应.结论 吉西他滨联合多西他赛治疗复发或难治性骨肉瘤具有一定的疗效,安全性高,值得临床推广应用.%Objective To evaluate the efficacy and safety of the combination of gemcitabine and docetaxel in patients with recurrent or refractory osteosarcoma. Methods Twenty-eight patients with recurrent or refractory osteosarcoma confirmed by histopathol-ogy were administrated with gemcitabine 1000mg/m2 ( day 1 and day 8 ) and docetaxel 75mg/m2 ( day 8 ) every 3 weeks. The overall response and toxicity were observed. Results Totally, 28 patients were entered and all of these patients were evaluated. Partial response was observed in 1 patient, stable disease was observed in 8 patients and progressive disease was observed in 19 patients. Overall response rate was 3. 6% (1/28) and the disease control rate was 32. 1% (9/28). Median time to progression and overall survival time were 6. 0 weeks(6-24) and 11.0 months(3-26) , respectively. The main toxic reactions were myelosuppression, digestive tract reaction and fatigue. No serious adverse event was observed. Conclusion The gemcitabine combined with docetaxel tends to show modest treatment efficacy and is well tolerated in patients with recurrent or refractory osteosarcoma.
展开▼
